Non-Invasive nasal tests to detect Alzheimer’s and related memory problems
Official title: Non-Invasive Diagnostic Assays for Neurodegenerative Diseases
Funded at Sonas Biotechnologies INC · NIH-11402931 · Data updated 2026-11-12
A small business project is developing easy, non-invasive nasal tests to detect early signs of Alzheimer’s disease and related cognitive issues by measuring biomarkers.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sonas Biotechnologies INC NIH-funded |
| Lab location | 1 site (Eugene, United States) |
| Project start | September 22, 2026 |
| Project end | September 21, 2027 |
| Funding year | 2026 |
| Award (this year) | $499,745 |
| NIH project number | 1R43AG097098-01A1 |
| Project ID | NIH-11402931 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals at risk for or showing signs of MCI or Alzheimer’s disease, including those with suspected early neurodegenerative changes.
✕Less likely to help
People without cognitive impairment or those whose disease does not influence biomarker levels in the nasal pathway may not benefit.
What this research studies
This project focuses on creating high-sensitivity nasal biomarkers tests to flag early neurodegenerative changes associated with MCI and Alzheimer’s disease. It aims to streamline sample collection and processing so tests could be done more simply and economically. If successful, these tests could support earlier interventions and help monitor disease progression or response to treatment. The work is in the Phase I SBIR stage, exploring feasibility of the approach and linking biomarker signals to disease status.
Why it matters
Potential benefit: If successful, patients could get earlier, less invasive detection and better monitoring of disease progression or treatment effects.
How similar studies have gone: Prior non-invasive biomarker approaches have shown promise, but nasal biomarkers for AD remain an emerging area with early positive signals.
Where this research is happening
-
Sonas Biotechnologies INC
Eugene, United States Active
Researchers
- Principal investigator: Naleway, John Joseph — Sonas Biotechnologies INC
- Study coordinator: Naleway, John Joseph
Related research
Other NIH-funded projects on the same topics.
-
Developing small molecules to treat TDP-43 related brain diseases
A potential new drug candidate (XL20) for diseases like Alzheimer’s and other dementias linked to TDP-43 protein problems is being developed and refined for people who live with these conditions.
-
Tau filament structure in Alzheimer’s and related dementias
Aims to map the detailed 3D shapes of tau protein filaments found in human brain diseases to help develop better diagnostics and treatments for Alzheimer’s-related dementias.
-
Targeting RNA Splicing Abnormalities in ALS/FTD
A research team aims to understand and correct abnormal RNA splicing in ALS and related brain diseases to help patients in the future.
-
Blood-brain barrier–friendly imaging agents for neurodegenerative diseases
A researcher team will test new imaging agents that can cross the brain barrier to help detect Alzheimer’s and related diseases earlier and more accurately.
-
Brain cell–derived EV markers to differentiate Alzheimer’s and related dementias
A Mayo Clinic team is testing brain-cell–specific tiny particles in blood to tell apart Alzheimer’s disease and similar dementias using advanced machine-learning analysis.
-
Fisetin approach to reduce vulnerability to community infections in aging veterans
A patient-friendly look at a study testing whether the natural compound fisetin can help aging Veterans stay healthier when they face common infections.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.